MIGUEL ANGEL
SERRA DESFILIS
CATEDRÁTICO/A DE UNIVERSIDAD
María
Buti Ferret
Publicaciones en las que colabora con María Buti Ferret (9)
2023
-
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602
-
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132
-
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction
Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162
2020
-
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study
Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 3, pp. 500-512
2017
-
Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System
Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282
-
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1
2015
-
High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain
Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486
-
Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery
Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153
2014
-
Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, Vol. 38, Núm. 5, pp. 418-429